BlackRock Amends Travere Therapeutics Stake (SC 13G/A)
Ticker: TVTX · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1438533
| Field | Detail |
|---|---|
| Company | Travere Therapeutics, Inc. (TVTX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock updated its stake in Travere Therapeutics, signaling its continued institutional interest.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating its ownership of Travere Therapeutics, Inc. common stock as of December 31, 2023. This filing, Amendment No. 9, updates their previous disclosures regarding their stake in the pharmaceutical company. For investors, this matters because BlackRock is a major institutional investor, and changes in their reported holdings can signal their confidence (or lack thereof) in Travere Therapeutics' future prospects, potentially influencing other investors.
Why It Matters
This filing shows BlackRock's updated ownership in Travere Therapeutics, providing transparency on a significant institutional investor's position, which can influence market perception and trading decisions.
Risk Assessment
Risk Level: low — This is a routine update from a large institutional investor and does not inherently signal a high-risk event for the company.
Analyst Insight
An investor should note BlackRock's continued presence as a significant shareholder in Travere Therapeutics, but this routine amendment alone doesn't provide enough detail to warrant immediate action without reviewing the specific changes in share count (which are not provided in this excerpt).
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Travere Therapeutics, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
- Amendment No. 9 (number) — the specific amendment number of this filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and 'Amendment No: 9' in the filing.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., as stated under the 'FILED BY' section of the filing.
What company's securities are the subject of this filing?
The subject company is Travere Therapeutics, Inc., as identified under 'SUBJECT COMPANY' and 'Name of Issuer' in the filing.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as explicitly stated on the cover page of the Schedule 13G.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), indicated by the 'X' next to '[X] Rule 13d-1(b)' on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding Travere Therapeutics, Inc. (TVTX).